Elon Musk’s brain-chip company, Neuralink, announced that it has received the U.S. Food and Drug Administration’s (FDA) “breakthrough device” designation for its experimental vision-restoring device, Blindsight. This designation is reserved for innovative medical devices that aim to treat or diagnose life-threatening conditions, with the goal of accelerating their development and regulatory review.
The Blindsight device has the potential to restore vision to people who have lost both eyes and their optic nerves. Musk shared this groundbreaking news on X, stating that Blindsight “will enable even those who have lost both eyes and their optic nerve to see.” However, Neuralink has not provided details on when the device might enter human trials. The FDA has also not commented on the timeline for these trials.
